Scouring through corporate communications and broker research isn’t enough Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The ...

A licensed attorney with nearly a decade of experience in content production, Valerie Catalano knows how to help readers digest complicated information about the law in an approachable way. Her ...

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...

When the IBM PC was new, I served as the president of the San Francisco PC User Group for three years. That’s how I met PCMag’s editorial team, who brought me on board in 1986. In the years since that ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. SpaceX is going all in on AI data centers in space — and the company kicked off its IPO week with a ...

As our economy, society and daily life become increasingly dependent on data, new college graduates entering the workforce need to have the skills to analyze data effectively and from multiple angles.

Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at the American Society of Clinical Oncology (ASCO ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Oncolytics Biotech (ONCY) is back on investors' radars after ...

A sharp fall in China’s crude oil imports during the Iran war has been instrumental in holding down oil prices and keeping the global economy humming. Clues are emerging in the mystery of the missing ...

Into Music is a podcast that explores the critical role that teachers, mentors, and tastemakers have in a musician’s musical development. Episodes feature discussion of the performers work and ...

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...